Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prothena has the GF Score of 74, which implies that the company
is
Likely to have average performance.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Prothena
is
Likely to have average performance.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Prothena (STU:0PT) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Prothena GF Score Related Terms
STU:0PT vs CTNM, ASMB, ARVN: GF Score Comparison
For the Biotechnology subindustry, Prothena's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prothena GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prothena's GF Score distribution charts can be found below:
* The bar in red indicates where Prothena's GF Score falls into.
Prothena (STU:0PT) has a GF Score of 74 as of Jul. 15, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Prothena and its competitors. This is 21% above median its historical median of 61.00. Over the past decade, Prothena's GF Score has ranged from 21.00 to 79.00.
Is Prothena's GF Score too high?
Prothena's current GF Score of 74 is 21% above median its 10-year median of 61.00. Over the past 10 years, this metric has ranged from a low of 21.00 to a high of 79.00. Overall, Prothena has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Prothena's GF Score compare to CTNM and ASMB?
Prothena's GF Score of 74 can be compared against companies in the Biotechnology industry. Historically, Prothena's own GF Score has ranged from 21.00 to 79.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Prothena and its competitors. Prothena's current GF Score is 74, which is 21% above median its own 10-year median of 61.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prothena stock overvalued right now?
Prothena (STU:0PT) has a current GF Score of 74. The stock's GF Value™ is €12.84, compared to a current price of €7.59 — trading 40.9% below its estimated fair value. The current GF Score is 74, which is 21% above median its 10-year median of 61.00. Prothena's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Prothena (STU:0PT), the current GF Score is 74 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prothena (STU:0PT) Overvalued in 2026?
Based on GuruFocus' analysis, Prothena stock appears to be undervalued.
The current stock price of €7.59 is trading 40.9% below its estimated GF Value™ of €12.84.
Key valuation signals for STU:0PT:
GF Score: 74 (21% above median its 10-year median of 61.00)
GF Value™: €12.84 vs. price of €7.59 (40.9% below fair value)
No single metric tells the full story. See the STU:0PT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
74GF Score
Get the complete analysis for STU:0PT
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0PT has been successfully added to your 
